Comparison 2. Gatifloxacin‐containing 4‐month ATT versus standard 6‐month ATT regimens.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Relapse	2	1633	Risk Ratio (M‐H, Fixed, 95% CI)	2.11 [1.56, 2.84]
2 Relapse: sensitivity analysis accounting for missing data	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Modified‐ITT analysis	2	1633	Risk Ratio (M‐H, Fixed, 95% CI)	2.11 [1.56, 2.84]
2.2 Per‐protocol analysis	2	1525	Risk Ratio (M‐H, Fixed, 95% CI)	2.11 [1.55, 2.87]
2.3 Modified‐ITT analysis (all eligible participants ‐ imputing missing data)	2	1851	Risk Ratio (M‐H, Fixed, 95% CI)	2.01 [1.53, 2.63]
3 Death from any cause	2	1886	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.53, 1.53]
4 Treatment discontinuation	2	1657	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.46, 1.08]
5 Positive sputum culture at 8 weeks	2	1818	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.80, 1.23]
6 Treatment failure	2	1657	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.51, 1.70]
7 Acquired drug resistance	1	301	Risk Ratio (M‐H, Fixed, 95% CI)	0.24 [0.01, 5.01]
8 Serious adverse events	2	1993	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.58, 1.77]